Menopause Publishes Pivotal Trial Results for Brisdelle™ (Paroxetine)...
MIAMI, FL and NEW YORK, NY, Sept. 18, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc., today announced the publication of results from its two Phase 3 clinical studies in Menopause, the...
View ArticleLigand Partner Pfizer Receives FDA Approval for DUAVEETM for the Treatment of...
(Source: Ligand Pharmaceuticals Inc) DUAVEE is the first and only therapy to pair conjugated estrogens with an estrogen agonist/antagonist, also known as a selective estrogen receptor modulator (SERM)...
View ArticleLigand Partner Pfizer Receives FDA Approval for DUAVEETM for the Treatment of...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Pfizer received approval today from the U.S. Food and Drug Administration (FDA) for DUAVEETM (conjugated...
View ArticleNew Survey Sheds Light on Moms' Perspectives About ADHD Medications
Moms of Children Taking ADHD Prescription Medication Feel Like They Are Doing the Right Thing, Yet Challenges and Knowledge Gaps Remain Google...
View ArticleMedicine count be causing morning leg pain
Q. I am healthy and in very good physical condition, but for a few years now I wake up early in the morning with leg pain. Sometimes it is so sharp that it almost knocks me to the floor. These cramps...
View ArticlePfizer Inc. Announces FDA Approval of DUAVEE™ (conjugated estrogens/...
(Source: Pfizer Inc) DUAVEE is the first and only therapy to pair conjugated estrogens with an estrogen agonist/antagonist, also known as a selective estrogen receptor modulator (SERM) [2] NEW...
View ArticlePfizer Inc. Announces FDA Approval of DUAVEE™ (conjugated estrogens/...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE), a leader in the development of treatments for menopausal symptoms, is pleased to announce that the United States Food and Drug Administration (FDA)...
View ArticleNoven Announces FDA Advisory Committee Vote on Investigational Low-Dose...
Tweet MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory Committee...
View ArticleNoven Pharmaceuticals, Inc. press release :First and Only FDA-approved,...
(Source: Hisamitsu Pharmaceutical Co Ltd) First and Only FDA-approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S. Pharmacies The availability of...
View ArticleData on Brisdelle™ (Paroxetine) Capsules, the First and Only FDA-Approved...
Download image Noven Pharmaceuticals, Inc. (PRNewsFoto/Noven Pharmaceuticals, Inc.) MIAMI, Fla. and NEW YORK, N.Y., Oct. 2, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc., today announced that 11...
View ArticleSurvey of Nurse Practitioners Finds Oral Estrogen Therapy Is Prescribed More...
Findings presented at Nurse Practitioners in Women's Health 14th Annual Premier Women's HealthCare Conference...
View ArticlePfizer (PFE) Affirms FDA Approval of Duavee (LGND)
Tweet Send to a Friend Get Alerts PFE Hot Sheet Price: $28.77 -0.83% Overall Analyst Rating: BUY (= Flat) Dividend Yield: 3.3% Revenue Growth %: -9.4% Trade PFE Now! Join SI Premium – FREE Pfizer,...
View ArticleMenopause Drugs from Depomed, Hisamitsu Offer Benefits
Drugs developed for menopausal hot flashes by Depomed Inc. (DEPO) and Hisamitsu Pharmaceutical Co. (4530) are effective, according to staff reviewers at the Food and Drug Administration. While...
View ArticleFDA approves first nonhormonal drug for hot flashes
Published July 01, 2013The Wall Street Journal The Food and Drug Administration Friday approved the first nonhormonal drug designed to treat hot flashes, one of the most bothersome symptoms of...
View ArticleNoven Announces FDA Advisory Committee Vote on Investigational Low-Dose...
Tweet MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory...
View ArticleFDA approves first nonhormonal drug for hot flashes
Published July 01, 2013The Wall Street Journal The Food and Drug Administration Friday approved the first nonhormonal drug designed to treat hot flashes, one of the most bothersome symptoms of...
View ArticleFirst nonhormonal treatment for hot flashes, Brisdelle, approved by FDA
Women with uncomfortable hot flashes now have a medication option that doesn't involve hormones. The U.S. Food and Drug Administration approved the first nonhormonal drug to treat moderate to severe...
View ArticleNoven Announces FDA Advisory Committee Vote on Investigational Low-Dose...
Tweet MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory...
View ArticleMenopause: Change of life has range of symptoms, treatments
">Related Menopause: 5 things to know According to Dr. Ted Quigley, an ob-gyn at Scripps Health in San Diego, the average age for menopause is 51, which he said has stayed steady since Grecian...
View ArticleMenopause Drugs from Depomed, Hisamitsu Offer Benefits
Drugs developed for menopausal hot flashes by Depomed Inc. (DEPO) and Hisamitsu Pharmaceutical Co. (4530) are effective, according to staff reviewers at the Food and Drug Administration. While...
View Article